Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction

What Was Tested

Researchers studied ANP (Atrial Natriuretic Peptide) in this randomized controlled trial publication.

The study evaluates the effect of atrial natriuretic peptide (ANP) compared with nitroglycerin (GTN) on left ventricular (LV) remodeling after first anterior acute myocardial infarction (AMI).

Why It Was Studied

Compared with GTN, ANP suppresses the renin-angiotensin-aldosterone system and endothelin-1 (ET-1), which stimulate LV remodeling.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

Sixty patients with a first anterior AMI were randomly divided into the ANP (n = 30) or GTN (n = 30) groups after direct percutaneous transluminal coronary angioplasty.

How the Study Was Run

The design is described as randomized.

The participants were allocated by chance, so the ANP (Atrial Natriuretic Peptide) group and the comparison group should start out alike.

The methods mention a period of one month.

The researchers evaluated LV ejection fraction (LVEF), end-diastolic volume index (LVEDVI) and end-systolic volume index (LVESVI) at the acute phase and after one month.

The researchers also measured neurohumoral factors during study drug infusion.

What Was Measured

The subject headings attached to it are Atrial Natriuretic Factor, Myocardial Infarction, Nitroglycerin and Ventricular Remodeling.

What This Means in Plain Language

The paper is a randomized study of ANP (Atrial Natriuretic Peptide) over one month.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2001 (Journal of the American College of Cardiology), a journal based in United States.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.